Health state utilities associated with weight loss: preferences of people with type 2 diabetes and obesity in Japan

References

• Chobot A, Gorowska-Kowolik K, Sokolowska M, et al. Obesity and diabetes-Not only a simple link between two epidemics. Diabetes Metab Res Rev. 2018;34(7):e3042.
   PubMed Web of Science ®Google Scholar
• Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med. 2007;356(3):213–215. doi:10.1056/NEJMp068177.
   PubMed Web of Science ®Google Scholar
• Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005;307(5708):373–375. doi:10.1126/science.1104342.
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, American Diabetes Association., et al. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes—2023. Diabetes Care. 2023;46(Supplement_1):S128–S139. doi:10.2337/dc23-S008.
   PubMedGoogle Scholar
• Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38(6):1161–1172. doi:10.2337/dc14-1630.
   PubMed Web of Science ®Google Scholar
• Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682–691. doi:10.1111/ijcp.12384.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409–418. doi:10.1016/j.diabet.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626. doi:10.1016/S0140-6736(23)01200-X.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155. doi:10.1016/S0140-6736(21)01324-6.
   PubMed Web of Science ®Google Scholar
• Brazier J, Ratcliffe J, Saloman J, et al. Measuring and valuing health benefits for economic evaluation. Oxford (UK): Oxford University Press; 2016.
   Google Scholar
• Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30(7):1267–1273. doi:10.1185/03007995.2014.899207.
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007;16(7):1251–1265. doi:10.1007/s11136-007-9226-0.
   PubMed Web of Science ®Google Scholar
• Matza LS, Yurgin N, Boye KS, et al. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23(9):2051–2062. doi:10.1185/030079907X219454.
   PubMed Web of Science ®Google Scholar
• Olofsson S, Norrlid H, Persson U. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden. J Med Econ. 2016;19(10):945–958. doi:10.1080/13696998.2016.1187152.
   PubMed Web of Science ®Google Scholar
• Rajan N, Boye KS, Gibbs M, et al. Utilities for type 2 diabetes treatment-related attributes in a South Korean and Taiwanese population. Value Health Reg Issues. 2016;9:67–71. doi:10.1016/j.vhri.2015.11.006.
   PubMedGoogle Scholar
• Ridderstråle M, Evans LM, Jensen HH, et al. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health Qual Life Outcomes. 2016;14(1):13. doi:10.1186/s12955-016-0411-0.
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Stewart KD, et al. Health state utilities associated with weight loss in type 2 diabetes and obesity. J Med Econ. 2022;25(1):14–25. doi:10.1080/13696998.2021.2002062.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-Mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623–633. doi:10.1016/S2213-8587(22)00188-7.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Chin R, Ozeki A, et al. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):634–644. doi:10.1016/S2213-8587(22)00187-5.
   PubMed Web of Science ®Google Scholar
• Kaku K, Yamada Y, Watada H, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab. 2018;20(5):1202–1212. doi:10.1111/dom.13218.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8(5):377–391. doi:10.1016/S2213-8587(20)30075-9.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Dilokthornsakul P, Sruamsiri R, et al. Cultural beliefs, utility values, and health technology assessment. Cost Eff Resour Alloc. 2018;16(1):19. doi:10.1186/s12962-018-0103-1.
   PubMed Web of Science ®Google Scholar
• Roudijk B, Donders ART, Stalmeier PFM. Cultural values: can they explain differences in health utilities between countries? Med Decis Making. 2019;39(5):605–616. doi:10.1177/0272989X19841587.
   PubMed Web of Science ®Google Scholar
• Wardle J, Haase AM, Steptoe A. Body image and weight control in young adults: international comparisons in university students from 22 countries. Int J Obes (Lond). 2006;30(4):644–651. doi:10.1038/sj.ijo.0803050.
   PubMed Web of Science ®Google Scholar
• Examination committee of criteria for 'obesity disease’ in Japan, Japan society for the study of obesity. New criteria for 'obesity disease’ in Japan. Circ J. 2002;66(11):987–992.
   PubMed Web of Science ®Google Scholar
• Gouda M, Matsukawa M, Iijima H. Associations between eating habits and glycemic control and obesity in Japanese workers with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2018;11:647–658. doi:10.2147/DMSO.S176749.
   PubMed Web of Science ®Google Scholar
• Kagawa M, Kerr D, Uchida H, et al. Differences in the relationship between BMI and percentage body fat between Japanese and Australian-Caucasian young men. Br J Nutr. 2006;95(5):1002–1007. doi:10.1079/bjn20061745.
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Yoshiike N, Osaka T, et al. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet. 2005;94:1–12.
   PubMedGoogle Scholar
• Yokote K, Sano M, Tsumiyama I, et al. Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. Diabetes Obes Metab. 2020;22(7):1102–1110. doi:10.1111/dom.14006.
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Stewart KD, et al. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. J Med Econ. 2019;22(8):806–813. doi:10.1080/13696998.2019.1609482.
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–230. doi:10.1007/s10198-010-0224-8.
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Jordan JB, et al. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Patient Prefer Adherence. 2018;12:971–979. doi:10.2147/PPA.S159620.
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Stewart KD, et al. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res. 2017;17(1):774. doi:10.1186/s12913-017-2648-7.
   PubMed Web of Science ®Google Scholar
• Matza LS, Cutts KN, Stewart KD, et al. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Qual Life Res. 2021;30(7):2033–2043. doi:10.1007/s11136-021-02808-2.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Ikeda S, Noto S, et al. Comparison of value set based on DCE and/or TTO data: scoring for EQ-5D-5L health states in Japan. Value Health. 2016;19(5):648–654. doi:10.1016/j.jval.2016.03.1834.
   PubMed Web of Science ®Google Scholar
• Ishii H, Takamura H, Nishioka Y, et al. Quality of life and utility values for cost-effectiveness modeling in Japanese patients with type 2 diabetes. Diabetes Ther. 2020;11(12):2931–2943. doi:10.1007/s13300-020-00938-3.
   PubMed Web of Science ®Google Scholar
• Nugraha GI, Tahapary DL, Hidayat RW, et al. The urgency in proposing the optimal obesity cutoff value in Indonesian population: a narrative review. Medicine 2022;101(49):e32256. doi:10.1097/MD.0000000000032256.
   PubMed Web of Science ®Google Scholar
• Zhou B, Meta C. Analysis group of China obesity task F. [predictive values of body mass index and waist circumference to risk factors of related diseases in chinese adult population]. Zhonghua Liu Xing Bing Xue Za Zhi. 2002;23(1):5–10.
   PubMedGoogle Scholar
• Japan Ministry of Health, Labour, and Welfare. National Health and Nutrition Survey Report 2019. https://www.mhlw.go.jp/bunya/kenkou/kenkou_eiyou_chousa.html
   Google Scholar
• Rowen D, Mukuria C, Bray N, et al. Assessing the comparative feasibility, acceptability and equivalence of videoconference interviews and face-to-face interviews using the time trade-off technique. Soc Sci Med. 2022;309:115227. doi:10.1016/j.socscimed.2022.115227.
   PubMed Web of Science ®Google Scholar